- Home
- BDSX vs LUNG Comparison
BDSX vs LUNG Comparison
Compare BDSX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDSX
- LUNG
- Stock Information
- Founded
- BDSX 2005
- LUNG 1995
- Country
- BDSX United States
- LUNG United States
- Employees
- BDSX N/A
- LUNG N/A
- Industry
- BDSX Precision Instruments
- LUNG Industrial Specialties
- Sector
- BDSX Health Care
- LUNG Health Care
- Exchange
- BDSX Nasdaq
- LUNG Nasdaq
- Market Cap
- BDSX 115.4M
- LUNG 124.0M
- IPO Year
- BDSX 2020
- LUNG 2020
- Fundamental
- Price
- BDSX $0.28
- LUNG $2.78
- Analyst Decision
- BDSX Strong Buy
- LUNG Buy
- Analyst Count
- BDSX 5
- LUNG 6
- Target Price
- BDSX $1.75
- LUNG $11.53
- AVG Volume (30 Days)
- BDSX 1.8M
- LUNG 311.3K
- Earning Date
- BDSX 08-06-2025
- LUNG 07-30-2025
- Dividend Yield
- BDSX N/A
- LUNG N/A
- EPS Growth
- BDSX N/A
- LUNG N/A
- EPS
- BDSX N/A
- LUNG N/A
- Revenue
- BDSX $74,463,000.00
- LUNG $87,473,000.00
- Revenue This Year
- BDSX $17.29
- LUNG $18.02
- Revenue Next Year
- BDSX $29.33
- LUNG $18.17
- P/E Ratio
- BDSX N/A
- LUNG N/A
- Revenue Growth
- BDSX 35.76
- LUNG 19.84
- 52 Week Low
- BDSX $0.17
- LUNG $2.50
- 52 Week High
- BDSX $2.04
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- BDSX 43.14
- LUNG 41.83
- Support Level
- BDSX $0.27
- LUNG $2.52
- Resistance Level
- BDSX $0.31
- LUNG $2.84
- Average True Range (ATR)
- BDSX 0.02
- LUNG 0.16
- MACD
- BDSX 0.01
- LUNG 0.04
- Stochastic Oscillator
- BDSX 45.45
- LUNG 46.36
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.